Abstract
Non-small cell lung cancer (NSCLC) accounts for 85% of the cases of lung cancer in the United States, and 70% of patients with NSCLC have locally advanced or metastatic disease at the time of diagnosis. The 5-year overall survival rate for patients with locally advanced NSCLC is 15% to 20%. The traditional treatment paradigm for unresectable locally advanced NSCLC consists of platinum-based chemotherapy with concurrent radiation. Evidence from phase 3 clinical trials has established a role for immunotherapy after chemoradiation, and emerging data continue to elucidate the expanding role of immunotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 212-217 |
| Number of pages | 6 |
| Journal | Clinical Advances in Hematology and Oncology |
| Volume | 18 |
| Issue number | 4 |
| State | Published - Apr 2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Carcinoma, Non-Small-Cell Lung/mortality
- Chemoradiotherapy
- Clinical Trials, Phase III as Topic
- Disease-Free Survival
- Humans
- Immunotherapy
- Lung Neoplasms/mortality
- Survival Rate
- United States/epidemiology
Fingerprint
Dive into the research topics of 'Emerging role of immunotherapy in locally advanced non-small cell lung cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver